Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H32N2O9.ClH |
Molecular Weight | 565.012 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@](O)(CCO)CC3=C(O)C4=C(C(=N)C5=C(OC)C=CC=C5C4=O)C(O)=C23
InChI
InChIKey=QVPRMGHPBJJSRU-IGAJXZAQSA-N
InChI=1S/C27H32N2O9.ClH/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29;/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17-,23+,27-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C27H32N2O9 |
Molecular Weight | 528.551 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
GPX-150 is an anthracycline compound that is being tested for treatment in patients with soft-tissue sarcomas. This doxorubicin (DOX) analog does not show the cumulative dose-dependent cardiotoxicity of DOX. It works by reducing the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible cardiotoxicity seen with DOX. Phase 1 clinical trials showed no irreversible, cumulative dose-dependent cardiotoxicity. A phase 2 study investigating the safety and efficacy of GPX-150 in patients with soft tissue sarcoma has been completed. No patients developed any evidence of irreversible, cumulative dose-dependent chronic cardiotoxicity. Toxicities reported include grade 3 anemia, neutropenia, and grade 4 leukopenia.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:49:11 GMT 2023
by
admin
on
Sat Dec 16 12:49:11 GMT 2023
|
Record UNII |
QFO4NOX87K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
490315
Created by
admin on Sat Dec 16 12:49:12 GMT 2023 , Edited by admin on Sat Dec 16 12:49:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QFO4NOX87K
Created by
admin on Sat Dec 16 12:49:12 GMT 2023 , Edited by admin on Sat Dec 16 12:49:12 GMT 2023
|
PRIMARY | |||
|
100000183623
Created by
admin on Sat Dec 16 12:49:12 GMT 2023 , Edited by admin on Sat Dec 16 12:49:12 GMT 2023
|
PRIMARY | |||
|
236095-24-2
Created by
admin on Sat Dec 16 12:49:12 GMT 2023 , Edited by admin on Sat Dec 16 12:49:12 GMT 2023
|
PRIMARY | |||
|
135446068
Created by
admin on Sat Dec 16 12:49:12 GMT 2023 , Edited by admin on Sat Dec 16 12:49:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |